ABSTRACT
Aims
To analyse content and emission data submitted by manufacturers for nicotine‐containing vaping products in the United Kingdom (UK) in accordance with the European Union Tobacco Products Directive.
Design
Analysis of ingredient and emission data reported for all e‐liquid‐containing e‐cigarettes, cartridges or refill containers notified to the Medicines and Healthcare Regulatory Agency (MHRA) from November 2016 to October 2017.
Setting
United Kingdom
Cases
A total of 40 785 e‐liquid containing products.
Measurements
The average number of ingredients per product, nicotine concentrations, frequency of occurrence ingredients and frequency and levels of chemical emissions.
Findings
Reports were not standardised in relation to units of measurement or constituent nomenclature. Products listed an average of 17 ingredients and 3.3% were reported not to contain nicotine. A total of 59% of products contained <12 mg nicotine per mL, and <1% were reported to have nicotine concentrations above the legal limit of 20 mg/mL. Over 1500 ingredients were reported, and other than nicotine the most commonly reported non‐flavour ingredients were propylene glycol (97% of products) and glycerol (71%). The most common flavour ingredients were ethyl butyrate (42%), vanillin (35%) and ethyl maltol (33%). The most frequently reported chemical emissions were nicotine (65%), formaldehyde (48%) and acetaldehyde (40%). The reporting of the concentration of emissions was not standardised; emissions were reported in a format allowing analysis of median estimated concentration for between 13% and 100% of products for each reported emission. Most of the frequently reported emissions, other than nicotine, were present in median estimated concentrations below 1 μg/L of inspired air, and with the exception of nicotine, acrolein and diacetyl, at median levels below European Chemicals Agency Long Term Exposure and United States (US) Department of Labor Occupational Safety and Health Administration (OSHA) limits, where these were available.
Conclusions
An analysis of reports to the United Kingdom’s Medicines and Healthcare products Regulatory Agency by manufacturers of vaping products shows that (i) these products have a large range of ingredients and emissions, (ii) the reporting system is unstandardized in terms of reporting requirements, and (iii) for quantified emissions, median levels are for the most part below published safe limits for ambient air.